Translational Research

The PCC’s newest mechanism, the Translational Research Fund (TRF) was introduced in 2017 to facilitate adoption of the PCC’s scientific and technological developments into laboratories that serve the anti-doping community. When appropriate, this is accomplished directly by the researchers themselves. In other cases, the PCC uses TRF funds to encourage additional R&D, identify commercialization viability and interest, and manage adoption of research results through licensing agreements, joint ventures, and other creative partnerships designed to facilitate adoption of PCC funded research.

The fund’s initial $800,000 investment was dispersed to three projects showcasing potential for real-world applicability: